GABA-A Receptor Modulators

About Draig Therapeutics

Draig Therapeutics is a private, Cambridge-based biotech that emerged from stealth in mid-2025 with a substantial $140 million Series A financing to advance its pipeline of novel neuromodulators. The company is led by a seasoned team, including CEO Ivana Magovčević-Liebisch and Board Chair Douglas E. Williams, and is backed by a top-tier investor syndicate. With a clear focus on addressing the significant unmet need in neuropsychiatry, Draig's strategy centers on developing best-in-class modulators of glutamate and GABA receptors, aiming to deliver transformative treatments for conditions like MDD.

Therapeutic Areas